连续监测NT-proBNP与儿童肺动脉高压疾病严重程度及预后的关联
本研究为荷兰儿童肺动脉高压国家网络2003-2017年的纵向队列研究,纳入82例患儿,每3-6个月检测NT-proBNP及疾病严重程度指标。结果显示,在整个病程中较高的NT-proBNP水平与更高的WHO功能分级、更低的6分钟步行距离z评分和TAPSE z评分相关,并预测死亡或(心肺)移植风险。连续监测NT-proBNP可提供重要的预后信息,辅助临床决策。
要点
- 儿童肺动脉高压病程中,NT-proBNP水平与WHO功能分级、6分钟步行距离和TAPSE均相关。
- NT-proBNP水平升高与死亡或(心肺)移植风险增加相关(HR 16.61)。
- 连续监测NT-proBNP可提供预后信息,辅助临床决策。
核心结论
- 在儿童肺动脉高压整个病程中,连续测量NT-proBNP与疾病严重程度和无移植生存相关。
- 随时间监测NT-proBNP水平可提供重要的预后信息,结合其他已确立的预后标志物支持临床决策。
研究设计与样本
- 本研究为荷兰儿童肺动脉高压国家网络2003年至2017年间开展的纵向队列研究,纳入82例肺动脉高压患儿。
- 每3至6个月收集NT-proBNP及疾病严重程度标志物(WHO功能分级、6分钟步行距离、三尖瓣环收缩期位移)数据。
- 主要结局指标为死亡或(心肺)移植,并比较存活者与非存活者随时间变化的NT-proBNP水平。
主要发现
- 患者中位年龄8.8岁(IQR 4.6-13.5岁),女性占61%,中位随访时间4.8年(IQR 1.9-10.0年)。
- 在整个病程中,较高的NT-proBNP水平与较高的WHO功能分级相关(β=0.526;95%CI 0.451-0.600)。
- 较高的NT-proBNP水平与较低的6分钟步行距离z评分相关(β=-0.587;95%CI -0.828至-0.346)。
- 较高的NT-proBNP水平与较低的TAPSE z评分相关(β=-0.783;95%CI -1.016至-0.549)。
- 较高的NT-proBNP水平与死亡或(心肺)移植风险升高相关(HR 16.61;95%CI 7.81-35.33)。
临床怎么用
- 在儿童肺动脉高压随访中,可每3至6个月连续监测NT-proBNP水平,作为评估疾病严重程度和预后的辅助指标。
- NT-proBNP水平升高或随时间上升提示死亡或移植风险增加,应结合WHO功能分级、6分钟步行距离和TAPSE等指标综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between serially measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) serum levels and disease severity in children with pulmonary arterial hypertension (PAH), and to assess its predictive value for death or (heart-)lung transplantation. STUDY DESIGN: This was a longitudinal cohort study of the Dutch National Network for Pediatric Pulmonary Hypertension conducted between 2003 and 2017. Data on NT-proBNP and disease severity markers (World Health Organization Functional Class [WHO-FC], 6-minute walking distance [6MWD], and tricuspid annular plane systolic excursion [TAPSE]) were collected every 3 to 6 months from 82 children with PAH. The outcome measure was death or (heart-)lung transplantation. Also, NT-proBNP levels over time were compared between survivors and nonsurvivors. RESULTS: The median patient age was 8.8 years (IQR, 4.6-13.5 years), and 61% were female. The median duration of follow-up was 4.8 years (IQR, 1.9-10.0 years). At all times during the course of disease, higher NT-proBNP levels were associated with higher WHO-FC (β = 0.526; 95% CI, 0.451-0.600), lower 6MWD z-score (β = -0.587; 95% CI, -0.828 to -0.346), lower TAPSE z-score (β = -0.783; 95% CI, -1.016 to -0.549), and elevated risk of death or (heart-)lung transplantation (hazard ratio 16.61; 95% CI, 7.81-35.33). Compared with survivors, nonsurvivors had NT-proBNP levels that were higher at first measurement and increased exponentially over time (P = .005). Changes in NT-proBNP serum level over time were predictive of outcome. CONCLUSIONS: Throughout the disease course of pediatric PAH, serial measurements of NT-proBNP are associated with disease severity and transplant-free survival. Monitoring NT-proBNP levels over time provides important prognostic information that can support clinical decision making in combination with other established prognostic markers.
引用
- Said F, Haarman MG, Roofthooft MTR, et al. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children. J Pediatr. 2020. PMID: 32113658. doi:10.1016/j.jpeds.2020.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。